1. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes by Elisa Rumi, Daniela Pietra, Virginia Ferretti, Thorsten Klampfl, Ashot S. Harutyunyan, Jelena D. Milosevic, Nicole C. C. Them, Tiina Berg, Chiara Elena, Ilaria C. Casetti, Chiara Milanesi, Emanuela Sant’Antonio, Marta Bellini, Elena Fugazza, Maria C. Renna, Emanuela Boveri, Cesare Astori, Cristiana Pascutto, Robert Kralovics, and Mario Cazzola Blood Volume 123(10):1544-1551 March 6, 2014 ©2014 by American Society of Hematology

2. Hematologic parameters in patients with CALR-mutated ET, JAK2 (V617F)-mutated ET, and JAK2 (V617F)-mutated PV. Data are shown in a box plot depicting the upper and lower adjacent values (highest and lowest horizontal line, respectively), upper and lower qua... Elisa Rumi et al. Blood 2014;123:1544-1551 ©2014 by American Society of Hematology

3. Granulocyte mutant allele burden in JAK2 (V617F)-mutated and in CALR-mutated myeloid neoplasms. Elisa Rumi et al. Blood 2014;123:1544-1551 ©2014 by American Society of Hematology

4. Relationship between granulocyte JAK2 (V617F)-mutant allele burden and hematologic parameters in patients with ET or PV. The mutant allele burden was directly correlated with Hb level (ρ = 0.53, P <.001) and hematocrit (ρ = 0.61, P <.001), and inversely c... Elisa Rumi et al. Blood 2014;123:1544-1551 ©2014 by American Society of Hematology

5. Cumulative incidence of polycythemic transformation, thrombotic events, myelofibrotic transformation, and leukemic transformation in patients with CALR- or JAK2-mutated ET and in those with PV. The cumulative incidences were estimated with a competing risk... Elisa Rumi et al. Blood 2014;123:1544-1551 ©2014 by American Society of Hematology